180 related articles for article (PubMed ID: 8199003)
1. An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Int J Exp Pathol; 1994 Apr; 75(2):111-6. PubMed ID: 8199003
[TBL] [Abstract][Full Text] [Related]
2. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis.
Sordet F; Aumjaud Y; Fessi H; Derouin F
Parasite; 1998 Sep; 5(3):223-9. PubMed ID: 9772721
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii.
Araujo FG; Huskinson-Mark J; Gutteridge WE; Remington JS
Antimicrob Agents Chemother; 1992 Feb; 36(2):326-30. PubMed ID: 1605598
[TBL] [Abstract][Full Text] [Related]
4. A morphological study of chronic cerebral toxoplasmosis in mice: comparison of four different strains of Toxoplasma gondii.
Ferguson DJ; Huskinson-Mark J; Araujo FG; Remington JS
Parasitol Res; 1994; 80(6):493-501. PubMed ID: 7808999
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii.
Djurković-Djaković O; Milenković V; Nikolić A; Bobić B; Grujić J
J Antimicrob Chemother; 2002 Dec; 50(6):981-7. PubMed ID: 12461021
[TBL] [Abstract][Full Text] [Related]
6. Rifabutin is active in murine models of toxoplasmosis.
Araujo FG; Slifer T; Remington JS
Antimicrob Agents Chemother; 1994 Mar; 38(3):570-5. PubMed ID: 8203856
[TBL] [Abstract][Full Text] [Related]
7. Effects of drug therapy on Toxoplasma cysts in an animal model of acute and chronic disease.
Gormley PD; Pavesio CE; Minnasian D; Lightman S
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1171-5. PubMed ID: 9620076
[TBL] [Abstract][Full Text] [Related]
8. Histopathological and ultrastructural assessment of atovaquone-proguanil hydrochloride combination in chronic murine toxoplasmosis.
Elmehankar MS; Elhenawy AA; Aboukamar WA; Elzoheiry MA; Nabih N
Ultrastruct Pathol; 2021 Nov; 45(6):376-383. PubMed ID: 34595988
[TBL] [Abstract][Full Text] [Related]
9. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate.
Djurković-Djaković O; Nikolić A; Bobić B; Klun I; Aleksić A
Microbes Infect; 2005 Jan; 7(1):49-54. PubMed ID: 15716077
[TBL] [Abstract][Full Text] [Related]
10. The timing of sulfadiazine therapy impacts the reactivation of latent Toxoplasma infection in IRF-8-/- mice.
Jost C; Reiter-Owona I; Liesenfeld O
Parasitol Res; 2007 Nov; 101(6):1603-9. PubMed ID: 17846793
[TBL] [Abstract][Full Text] [Related]
11. SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
Shubar HM; Lachenmaier S; Heimesaat MM; Lohman U; Mauludin R; Mueller RH; Fitzner R; Borner K; Liesenfeld O
J Drug Target; 2011 Feb; 19(2):114-24. PubMed ID: 20367080
[TBL] [Abstract][Full Text] [Related]
12. Atovaquone maintenance therapy prevents reactivation of toxoplasmic encephalitis in a murine model of reactivated toxoplasmosis.
Dunay IR; Heimesaat MM; Bushrab FN; Müller RH; Stocker H; Arasteh K; Kurowski M; Fitzner R; Borner K; Liesenfeld O
Antimicrob Agents Chemother; 2004 Dec; 48(12):4848-54. PubMed ID: 15561866
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil.
Alves CF; Vitor RW
Parasite; 2005 Jun; 12(2):171-7. PubMed ID: 15991831
[TBL] [Abstract][Full Text] [Related]
14. The activity of atovaquone (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine.
Araujo FG; Lin T; Remington JS
J Infect Dis; 1993 Feb; 167(2):494-7. PubMed ID: 8421189
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.
Romand S; Pudney M; Derouin F
Antimicrob Agents Chemother; 1993 Nov; 37(11):2371-8. PubMed ID: 8285620
[TBL] [Abstract][Full Text] [Related]
16. Use of rifabutin in combination with atovaquone, clindamycin, pyrimethamine, or sulfadiazine for treatment of toxoplasmic encephalitis in mice.
Araujo FG; Suzuki Y; Remington JS
Eur J Clin Microbiol Infect Dis; 1996 May; 15(5):394-7. PubMed ID: 8793398
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo effects of rifabutin alone or combined with atovaquone against Toxoplasma gondii.
Romand S; Della Bruna C; Farinotti R; Derouin F
Antimicrob Agents Chemother; 1996 Sep; 40(9):2015-20. PubMed ID: 8878573
[TBL] [Abstract][Full Text] [Related]
18. Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii.
El-Zawawy LA; El-Said D; Mossallam SF; Ramadan HS; Younis SS
Acta Trop; 2015 Jan; 141(Pt A):103-11. PubMed ID: 25305510
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the efficacy of atovaquone alone or in combination with azithromycin against acute murine toxoplasmosis.
Moshkani SK; Dalimi A
Vet Res Commun; 2000 Apr; 24(3):169-77. PubMed ID: 10836275
[TBL] [Abstract][Full Text] [Related]
20. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis.
Schöler N; Krause K; Kayser O; Müller RH; Borner K; Hahn H; Liesenfeld O
Antimicrob Agents Chemother; 2001 Jun; 45(6):1771-9. PubMed ID: 11353624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]